STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-249)	MIPASETAMAB
PRONUNCIATION	mip” a set’ a mab
THERAPEUTIC CLAIM	Treatment of solid tumors

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human receptor tyrosine kinase Axl) (human-Mus musculus monoclonal 1H12 γ1-chain), disulfide with human-Mus musculus monoclonal 1H12 κ-chain, dimer, 302,302'-bis[N-[O-2-(acetylamino)-6-azido-2,6-dideoxy-β-D- galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→6)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparagine] (Source : CAS)

2. immunoglobulin G1-kappa, anti-[*Homo sapiens* Tyrosine-protein kinase receptor UFO (AXL oncogene; EC=2.7.10.1)]; humanized monoclonal antibody; γ1 heavy chain humanized (1-451) [VH humanized (*Homo sapiens* IGHV3-30*03 (93%) –(IGHD)-IGHJ4*01 (92%)] [8.8.15] (1-122) *Homo sapiens* IGHG1*03 {CH1[R^{97}>K(219)], CH3[K^{107}>del(452)]} (123-451)], (225-215')-disulfide with κ light chain humanized (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84%) -IGKJ4*01 (91%))[7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (231-231'':234-234'')-bisdisulfide, produced in Chinese CHO cells, glycoform alfa.

STRUCTURAL FORMULA

Heavy chains X & X''

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMSWVRQA	PGKGLEWVAT	50
ISSGGSYTYY	PDSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARHP	100
IYYTYDDTMD	YWGQGTTVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200
QTYICNVNHK	PSNTKVDKKV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300
YNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE	350
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTP	400
PVLDSDGSFF	LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNH	YTQKSLSLSP	450
G					451

Light chains X' & X'''

EIVLTQSPGT	LSLSPGERAT	LSCSASSSVS	SGNFHWYQQK	PGLAPRLLIY	50'
RTSNLASGIP	ARFSGSGSGT	DFTLTISSLE	PEDFAVYYCQ	QWSGYPWTFG	100'
GGTKLEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDSK	DSTYSLSSTL	TLSKADYEKH	KVYACEVTHQ	200'
GLSSPVTKSF	NRGEC				215'

Disulfide bridges location

22-96	22"-96"	23'-89'	23'"-89'"	135'-195'	135'"-195'"	149-205	149"-205'"
215'-225921	215'"-225"	231-231"	234-234"	266-326	266"-326"	372-430	372"-430"

Chemically modified sites (Q & N)

Q 1 , 1" pyroglutamyl	

N 302 , 302"-bis{*N*-[*O*-2-(acetylamino)-6-azido-2,6-dideoxy-β-D-galactopyranosyl-(1→4)-*O*-[6-deoxy-α-L-galactopyranosyl-(1→6)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparagine}

MOLECULAR FORMULA	$C_{6472}H_{9946}N_{1714}O_{2024}S_{44}$ (not glycosylated)
MOLECULAR WEIGHT	145.56 kDa
TRADEMARK	None as yet
SPONSOR	ADC Therapeutics
CODE DESIGNATIONS	1H12-GaINAcN3, 1H12-HAKB
CAS REGISTRY NUMBER	2361055-48-1
UNII	DCI3L5GHC9
WHO NUMBER	11483

gbk